Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study

Even in the era of novel targeted agents, switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely used in treating metastatic castration-resistant prostate cancer (mCRPC), especially in undeveloped countries. However, whether prior treatment with a second-line NSAA would impact t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jin-Ge, Liu, Jian-Dong, Shen, Peng-Fei, Tang, Xin, Sun, Guang-Xi, Zhang, Xing-Ming, Chen, Jun-Ru, Shu, Kun-Peng, Shi, Ming, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219304/
https://www.ncbi.nlm.nih.gov/pubmed/30106011
http://dx.doi.org/10.4103/aja.aja_58_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219304/
https://www.ncbi.nlm.nih.gov/pubmed/30106011
http://dx.doi.org/10.4103/aja.aja_58_18

Ejemplares similares